The goal of TDM is to use appropriate concentrations of difficult-to-manage medications to optimise clinical outcomes in patients in various clinical situations. The Therapeutic Drug Monitoring (TDM) programme was launched in June 2013 as a Pilot programme to evaluate the performance of our “in-house” liquid material as compared with commercially available lyophilised material. This programme is now accredited for 14 different therapeutic drugs, the benefits of registering in this programme include:
A Whole Blood Immunosuppressants programme is available for Ciclosporin, Sirolimus and Tacrolimus.
Therapeutic Drug Monitoring
The base material is “off the clot” sterile human serum, tested negative forHIV, Hep B and C at donor level. Each therapeutic drug is gravimetrically added, the “weighed-in” value and its known linear dilution is used to calculate the target concentration. A linear series of pools are prepared using calibrated and certified equipment allowing full gravimetric traceability.
Frequency: Monthly
Samples per set: 3 x 1mL samples
Therapeutic Drug Monitoring Programme | ||
---|---|---|
Analyte | Approx. Range Covered | |
Amikacin | 0 - 35 | mg/L |
Carbamazapine | 0 - 20 | mg/L |
Digoxin | 0 - 6 | µg/L |
Gentamicin | 0 - 5 | mg/L |
Lamotrigine | 0 - 30 | mg/L |
Lithium | 0 - 2.5 | mmol/L |
Methotrexate | 0 - 1.5 | µmol/L |
Phenobarbital | 0 - 65 | mg/L |
Phenytoin | 0 - 30 | mg/L |
Teicoplanin | 0 - 70 | mg/L |
Theophylline | 0 - 30 | mg/L |
Tobramycin | 0 - 15 | mg/L |
Valproic acid | 0 - 175 | mg/L |
Vancomycin | 0 - 50 | mg/L |
Whole Blood Immunosuppressants | ||
- Ciclosporin | 0 - 600 | µg/L |
- Sirolimus | 0 - 20 | µg/L |
- Tacrolimus | 0 - 15 | µg/L |
Related Documents